Ruth Howells
Senior Director, Health Technology Assessment
Ruth is Head of Health Technology Assessment (HTA) at Clarivate. Ruth has overall responsibility for our Global HTA services and has been extensively involved in the development and strategic direction of HTAs, contributing in-depth knowledge of procedural processes.
Ruth oversees our global HTA services from early scientific advice, through local submissions and global HTA programs to post-submission support. With extensive experience of managing HTA submissions globally, Ruth works closely with our clients and in-house team, advising manufacturers on their role and requirements, and significantly contributes to the development and communication of the HTA strategy and evidence generation planning from an early stage.
Prior to joining Clarivate, Ruth worked for the National Institute for Health and Care Excellence (NICE) and has over 20 years’ experience in health outcomes research. Ruth has an MSc in Health Economics from the University of York and her experience in health outcomes research covers a wide range of therapeutic areas including, oncology (cervical cancer, head and neck cancer, colorectal cancer, breast cancer), respiratory disease, cardiology, nephrology, gynecology, gastroenterology and dermatology. Ruth is an expert in HTA for rare diseases and in innovative therapies such as cell and gene therapies.
Latest news
Clarivate Launches Derwent Patent Monitor to Enable Fast and Accurate Decision-making with AI
New enterprise solution streamlines IP and R&D patent reviews and accelerates freedom to operate, patentability, and infringement related decisions London, U.K. November 24, 2025. Clarivate Plc (NYSE:CLVT), a leading global provider…
Clarivate RiskMark Wins 2025 LegalTech Breakthrough Award For “LegalTech Predictive AI Solution of the Year”
Annual awards program recognizes companies and products driving innovation in the global legal technology industry AI-powered RiskMark delivers near-instant, data-backed insights London, U.K. November 13, 2025. Clarivate Plc (NYSE:CLVT), a…
